insights_auto
Why is DMYD-B up 3.47%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 1.01
arrow_upward
+3.47%(+0.034) 1D
Oct 12, 5:29:58 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 0.98
High
SEK 1.04
Low
SEK 0.98
Mkt. cap
153.60M
Avg. vol.
773.64K
Volume
796.60K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
Open
SEK 0.98
High
SEK 1.04
Low
SEK 0.98
Mkt. cap
153.60M
Avg. vol.
773.64K
Volume
796.60K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
News stories
From web sources and news partners
FXStreet
·
23 minutes ago
Can the S&P 500 continue its rally?
TradingView
·
25 minutes ago
S&P 500 expected to see 25% EPS growth as earnings kick off
Barron's
·
25 minutes ago
eBay Stock Leads the S&P 500 After Morgan Stanley Names It a Top Pick
TradeWinds News
·
3 days ago
Nordic American Tankers top stock as shipping crushes S&P 500 in unprecedented quarter
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB